Anti-Tuberculosis Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Disease Type (Active TB, Latent TB, Others), by Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others), by End User (Hospitals, Specialty Clinics, Homecare, others), by region, and
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAnti-Tuberculosis Therapeutics Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Disease Type (Active TB, Latent TB, Others), by Diagnosis and Treatment (Diagnosis (Blood Tests, Imaging Tests, Sputum Tests, Others), Treatment (First Line of Drugs, Second Line of Drugs, others), others), by End User (Hospitals, Specialty Clinics, Homecare, others), by region, and
| Forecast Period | 2024-2028 |
| Market Size (2022) | 1320.50 million |
| CAGR (2023-2028) | 5.90 % |
| Fastest Growing Segment | Isoniazid Segment |
| Largest Market | North America |
Market Overview
Global Anti-Tuberculosis Therapeutics Market has valued at USD 1320.50 million in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 5.90% through 2028.
The emergence of drug-resistant TB strains, such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), has driven the development of new and more effective anti-TB drugs.
Key Market Drivers
Emergence of Drug-Resistant TB Strains
Drug-resistant TB occurs when the bacterium that causes TB, Mycobacterium tuberculosis, becomes resistant to one or more of the drugs commonly used to treat the disease.
One of the primary factors driving drug resistance is the incomplete or inadequate treatment of TB. When patients do not complete the full course of their prescribed TB medications or when the drugs are not administered correctly, it creates conditions that allow the TB bacteria to develop resistance to the drugs. The inappropriate use of antibiotics, including the use of TB drugs for non-TB infections or the use of low-quality or substandard medications, can contribute to drug resistance. Patients may fail to adhere to their TB treatment regimens for various reasons, such as experiencing side effects, stigma associated with TB, or challenges with accessing healthcare services. Non-adherence can result in treatment failure and drug resistance. Drug-resistant TB strains can be transmitted from person to person. Close contact with an individual infected with a drug-resistant strain can lead to new cases of drug-resistant TB. Poor infection control measures in healthcare settings can facilitate the spread of drug-resistant TB strains, particularly in hospitals and clinics. In some regions, there may be limited access to second-line anti-TB drugs or diagnostic tools to detect drug resistance. This can delay the identification and appropriate treatment of drug-resistant cases. Individuals with compromised immune systems, such as those living with HIV, are at higher risk of developing drug-resistant TB due to their reduced ability to fight off the infection. This factor will help in the development of the
Increasing Antibiotic Resistance Concerns
Antibiotic resistance concerns are particularly relevant in the context of drug-resistant TB. TB is caused by Mycobacterium tuberculosis, a bacterium that can develop resistance to the antibiotics used to treat it. This resistance can occur when TB bacteria are exposed to anti-TB drugs, and some of them mutate or acquire resistance mechanisms. The emergence of drug-resistant TB strains, such as multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), has become a serious global health challenge. Drug-resistant TB is more difficult and expensive to treat than drug-susceptible TB. It often requires the use of second line and third-line drugs, which are less effective, more toxic, and more expensive than first-line drugs. The treatment regimens for drug-resistant TB are also longer, lasting for up to two years or more. This complexity and the associated challenges in treating drug-resistant TB drive the demand for anti-TB therapeutics. The rise of drug-resistant TB strains has created an urgent need for new and more effective anti-TB drugs. Traditional first-line TB drugs are no longer effective against some strains, necessitating the development of novel treatment options. Pharmaceutical companies, researchers, and public health organizations are investing in the discovery and development of new drugs to combat drug-resistant TB.
Antibiotic resistance concerns have spurred increased research and development efforts in the field of TB therapeutics. Researchers are exploring new drug candidates, combination therapies, and treatment regimens to address drug-resistant TB effectively. Drug-resistant TB is not limited to specific regions or countries; it is a global health threat. The spread of drug-resistant TB strains across borders and the potential for outbreaks pose a risk to public health worldwide. This recognition of the global impact of drug-resistant TB has led to heightened efforts to combat it. The concern over antibiotic resistance has also led to innovations in TB diagnostics. Rapid molecular tests and genotyping techniques can help identify drug-resistant TB strains more quickly, allowing for the timely adjustment of treatment regimens. Antibiotic resistance concerns have prompted policy changes and advocacy efforts aimed at strengthening TB control programs, improving treatment adherence, and promoting the responsible use of TB drugs to minimize the development of resistance. This factor will pace up the demand of the
Technological Advancements
GeneXpert is a rapid molecular diagnostic tool that can detect TB and drug-resistant TB within hours. It has revolutionized TB diagnosis by providing accurate and quick results, allowing for faster initiation of appropriate treatment. Line probe assays, such as the GenoType MTBDRplus assay, are used to detect drug resistance in TB strains. They provide information about resistance to key anti-TB drugs, helping clinicians tailor treatment regimens.
Technological advances have facilitated the development of new TB vaccine candidates. Recombinant DNA technology and novel adjuvants are being used to create more effective vaccines for TB prevention. Advances in drug delivery technologies have led to the development of novel drug formulations, such as nanoparticles and microparticles, to enhance drug delivery and improve treatment outcomes. Understanding how an individual's genetic makeup affects their response to TB drugs is crucial. Pharmacogenomic studies help personalize treatment regimens to maximize effectiveness and minimize side effects. Telemedicine and mHealth technologies enable healthcare providers to remotely monitor TB patients, ensure treatment adherence, and provide support, especially in resource-constrained settings. AI and machine learning algorithms are used for data analysis, drug discovery, and predicting drug resistance. They can help identify patterns in large datasets and optimize treatment strategies. Advances in point-of-care testing devices make it possible to perform TB diagnosis and drug resistance testing in decentralized healthcare settings, improving access to care. Mobile apps and SMS-based reminders are being used to enhance patient adherence to TB treatment regimens. These technologies help patients stay on track with their medications. Biotechnological approaches, such as the production of recombinant proteins, are used to develop new diagnostic assays and potential therapeutic agents for TB. This factor will accelerate the demand of the
Key Market Challenges
Stigma and Social Determinants
TB has historically carried a social stigma due to its contagious nature. People with TB may face discrimination and social isolation, which can discourage them from seeking diagnosis and treatment. Individuals diagnosed with TB may internalize societal stigma, leading to feelings of shame and guilt. This self-stigma can negatively affect mental health and willingness to adhere to treatment.
Access to Medications
In some regions, there may be limited availability of essential anti-TB medications, particularly in rural or remote areas. This can result from challenges in drug procurement, distribution, and supply chain management. The cost of anti-TB medications can be a significant barrier to access, particularly for individuals and communities with limited financial resources. Even when medications are found at, high prices can prevent people from obtaining them.
Key Market Trends
Treatment Regimen Simplification
Traditional TB treatment regimens often involve multiple pills taken daily for several months. Simplified regimens aim to reduce the number of pills, making it easier for patients to adhere to their treatment plans. Fixed-Dose Combinations (FDCs) combine multiple anti-TB drugs into a single tablet, reducing the complexity of treatment. This approach simplifies dosing schedules and enhances patient adherence. Efforts are underway to develop shorter-duration treatment regimens for TB. For example, some clinical trials have explored the feasibility of shorter treatment courses, such as the 4-month regimen for rifampin-sensitive TB. Simplified regimens may involve fewer clinic visits for drug administration or monitoring. This is particularly important for patients who face challenges in accessing healthcare facilities. Integrating TB treatment with other healthcare services, such as HIV care, maternal and child health, and non-communicable disease management, can simplify care for patients with multiple health needs. Developing pediatric-friendly formulations of anti-TB drugs, including child-appropriate FDCs and liquid formulations, simplifies treatment for children with TB. Mobile health (mHealth) technologies and digital tools can provide treatment reminders, track medication adherence, and support patients in adhering to their treatment regimens. Community health workers and TB treatment supporters can play a crucial role in simplifying treatment by delivering medications to patients in their communities and providing support. Improved diagnostics, such as molecular tests that rapidly detect TB and drug resistance, contribute to more precise treatment decisions and regimens.
Segmental Insights
Type Insights
In 2022, the Global Anti-Tuberculosis Therapeutics Market largest share was held by Active TB segment and is predicted to continue expanding over the coming years.
Application Insights
In 2022, the Global Anti-Tuberculosis Therapeutics Market largest share was held by Isoniazid segment and is predicted to continue expanding over the coming years.
End-User Insights
Hospital
Regional Insights
The North America region dominates the Global Anti-Tuberculosis Therapeutics Market in 2022. North America has a strong presence of pharmaceutical companies, research institutions, and healthcare organizations that contribute to the development of new anti-TB drugs, diagnostics, and vaccines. Innovations from North American institutions can have a global impact. The United States has provided funding and support for international TB control programs through organizations like the U.S. Agency for International Development (USAID) and the Centers for Disease Control and Prevention (CDC). These initiatives have helped address TB in high-burden countries.
Recent Developments
- In March 2022, as part of its commitment to the Corporate TB Pledge, ajoint initiative with the Central TB Division, Ministry of Health and FamilyWelfare in India, and United States Agency for International Development(USAID), Johnson & Johnson India announced the launch of a youth-focused,digital-first initiative #BeTheChangeForTB. This initiative supports the IndianGovernment's goal to end TB. The #BeTheChangeForTB programme targets young people in India since theyare most suited to lead the public in changing their behaviours, which wouldhelp to dramatically scale-up the battle against tuberculosis. The project willalso dispel popular myths about TB and provide the correct information on thediagnosis and treatment of the illness. The initiative's communication andsocial mobilisation components would involve a variety of online and offlineactivities, as well as collaboration with state and district health agencies,the National Tuberculosis Elimination Programme (NTEP), and localneighbourhoods.
- In September 2021, as part of the three-drug "BPaL" regimen,non-profit medication developer TB Alliance has awarded global pharmaceuticalgiant Lupin Limited (Lupin) a non-exclusive licence to produce the anti-TBmedicine pretomanid. When the lengthy, intricate, decades-old TB drug regimen is administeredincorrectly or when TB patients quit taking their medications before thedisease has been eliminated from their bodies, drug-resistant TB develops,emphasising the urgent need to create better and more efficient treatmentregimens. Like drug-sensitive TB, once a drug-resistant strain has emerged, itcan be spread straight from one person to another through the air.Drug-resistant tuberculosis affects more than 500,000 people yearly, and itsexpansion makes it difficult to contain the epidemic.
Key Market Players
- AstraZenecaPlc.
- Johnson& Johnson Private Limited
- Eli Lillyand Company
- F.Hoffmann-La Roche Ltd.
- Mylan N.V.
- TevaPharmaceutical Industries Ltd.
- Sanofi SA
- NovartisAG
- SunPharmaceutical Industries Ltd.
- Merck& Co., Inc.
| By Disease Type | By Diagnostic and Treatment | By End-User | By Region |
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy